Published in final edited form as:

Cancer Epidemiol Biomarkers Prev. 2012 November ; 21(11): 2014–2021. doi:
10.1158/1055-9965.EPI-12-0700-T.

Prospective study of genomic hypomethylation of leukocyte DNA and colorectal cancer risk

Wen-Yi Huang¹, L. Joseph Su², Richard B. Hayes³, Lee E. Moore¹, Hormuzd A. Katki¹,
Sonja I. Berndt¹, Joel L. Weissfeld⁴, Srinivasan Yegnasubramanian⁵, and Mark P. Purdue¹

¹Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD

²Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD

³Division of Epidemiology, New York University School Of Medicine, New York, NY

⁴Department of Epidemiology, University of Pittsburgh Cancer Institute, Pittsburgh, PA

⁵Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

Abstract

Background—Systematic genome-wide reductions of methylated cytosine (5-mC) levels have been observed in colorectal cancer tissue and are suspected to play a role in carcinogenesis, possibly as a consequence of inadequate folate intake. Reduced 5-mC levels in peripheral blood leukocytes have been associated with increased risk of colorectal cancer and adenoma in cross-sectional studies.

Methods—To minimize disease- and/or treatment-related effects, we studied leukocyte 5-mC levels in prospectively collected blood specimens of 370 cases and 493 controls who were cancer-free at blood collection from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Leukocyte 5-mC level was determined by an HPLC/Tandem Mass Spectrometry method and expressed as the relative amount of methyl- to total cytosine residues, or %5-mC. We estimated the association between colorectal cancer risk and %5-mC categories by computing odds ratios (ORs) and 95% confidence intervals (CIs) through logistic regression modeling.

Results—We observed no dose-dependent association between colorectal cancer and %5-mC categories (lowest tertile vs. highest: OR=1.14, 95% CI=0.80–1.63; *P*trend=0.51). However, among subjects whose 5-mC levels were at the highest tertile, we observed an inverse association between natural folate intake and colorectal cancer (highest tertile of natural folate vs. lowest: OR=0.35, 95% CI=0.17–0.71; *P*trend=0.003; *P*interaction=0.003).

Conclusions—This prospective investigation show no clear association between leukocyte 5-mC level and subsequent colorectal cancer risk, but a suggestive risk modification between 5-mC level and natural folate intake.

Impact—Adequate folate status may protect against colorectal carcinogenesis through mechanisms involving adequate DNA methylation in the genome.

Correspondence: Wen-Yi Huang, Ph.D., Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Boulevard, EPS 8110, MSC 7240, Bethesda, Maryland 20892-7240; Phone: 301-435-4710; Fax: 301-402-1819; huangw@mail.nih.gov.

Conflict of interest: the authors have no conflicts of interest to disclose

Keywords

5-mC; PLCO; folate; colorectal

INTRODUCTION

DNA methylation plays an important role in regulating a variety of cellular processes. The presence of DNA methylation is responsible for X-chromosome inactivation, gene silencing, imprinting and repression of repetitive elements and endogenous retroviruses, while the absence of methylation in CpG islands near promoter regions is necessary for transcription of specific genes to proceed. Both systematic genome-wide (global) reductions of methylated cytosines and region-specific increases of methylated cytosines in CpG islands are common epigenetic events thought to play a role in carcinogenesis(1;2). While hypermethylation occurs chiefly in gene promoter regions affecting gene control via impairing transcription, genomic hypomethylation occurs not only in transcription control regions such as promoters, but also in repetitive DNA sequences, such as satellite- and LINE- repeats, retrotransposons, and endogenous retroviral elements, causing altered chromatin structure, chromosomal instability, aneuploidy, and higher mutation rates(3;4).

Genomic DNA hypomethylation has been observed in somatic tissue of sporadic colorectal cancer(5), its precursor adenoma(6), and even adjacent normal appearing mucosa of patients with colorectal neoplasia(7). It is thought to occur gradually in an age-dependent manner, and to play an early role in the process of colorectal carcinogenesis(8). Genomic DNA methylation levels in colorectal tumors have been positively correlated with microsatellite instability and the CpG island methylator phenotype(9;10), whereas hypomethylation has been associated with poor prognosis(11). It has been speculated that the effects of reduced DNA hypomethylation (i.e., sufficient methylation) may mediate the reported reduction in colorectal cancer risk associated with high dietary intake of folate, a B vitamin present in green leafy vegetables, fruits, dairy products, and potatoes that provides one-carbon groups for DNA synthesis, repair, and methylation(12;13).

Two recent cross-sectional studies of colorectal cancer and adenoma measured genomic DNA methylation levels in peripheral blood leukocyte DNA as a surrogate for methylation in colorectal tissue; in both studies, hypomethylation was significantly associated with increased risk(14;15). However, given that both studies used blood specimens collected after cancer diagnosis, the possibility that the associations reflect reverse causation due to disease-related effects cannot be ruled out.

In the present study, we evaluated genomic DNA hypomethylation in prospectively collected peripheral leukocytes in relation to subsequent colorectal cancer risk and its potential interrelationship with folate deficiency and other risk factors.

MATERIALS AND METHODS

The PLCO Trial

The Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial is a randomized trial of approximately 155,000 men and women aged 55–74, enrolled between 1993 and 2001 from 10 U.S. centers (Birmingham AL, Denver CO, Detroit MI, Honolulu HI, Marshfield WI, Minneapolis MN, Pittsburgh PA, Salt Lake City UT, St Louis MO, and Washington DC), to determine whether screening reduces the mortality from prostate, lung, colorectal and ovarian cancers(16). Participants randomized to the screening arm underwent a 60-cm flexible sigmoidoscopy examination at study entry (T0) and at year 3 or year 5 of

the Trial (T3/T5; the protocol for the second sigmoidoscopy changed from year 3 to year 5 in 1999). Subjects with screen-detected abnormalities were referred to their personal physician for diagnostic follow-up(17). Subjects were also sent annual questionnaires asking about recent cancer diagnoses. Medical records were obtained for all subjects with an abnormal sigmoidoscopic examination, or all colorectal cancers reported on the questionnaires or through death certificates, therefore, all colorectal cancers were pathologically verified. Information on colorectal cancer location (proximal or distal) and stage (I, II, III, or IV) were based on pathology reports. In the present analysis, we considered cecum, appendix, ascending colon, hepatic flexure of colon, transverse colon, and splenic flexure of colon as proximal colon, descending colon, sigmoid colon, rectosigmoid junction as distal colon, and rectum. The Trial was approved by the institutional review boards of the National Cancer Institute and the 10 screening centers.

Study Population

Participants were eligible for this study if they: a) were randomized to the screening arm; b) consented to participate in PLCO ancillary epidemiologic studies of cancer and related diseases; c) completed a risk factor questionnaire; d) provided a blood sample with DNA source material available in the biorepository(18); and e) reported a negative history of colorectal cancer. As a result, we identified 462 pathologically-verified colorectal cancer cases and 61,445 healthy controls free of colorectal cancer, eligible for study, from whom 528 controls were selected, frequency-matched to the respective case series on age (55–59, 60–64, 65–69, 70–74 years), gender, race (white, black, other), year of randomization, and year since initial sigmoidoscopy screening. Subjects with colorectal cancer (61 cases) or any other cancer (6 cases and 9 controls) diagnosis prior to the leukocyte DNA blood draw, or those with insufficient leukocyte DNA quantity or unsuccessful determination of genomic methylation status (25 cases and 26 controls) were further excluded, resulting in 370 cases and 493 controls for the present analysis. The length of follow-up for selected cases and controls from study entry until selection ranged between 0 to 10 years (median = 3, S.D. = 2.7).

Questionnaire Data

Participants completed a baseline risk factor questionnaire, in which they reported their race, education, body size, use of tobacco, aspirin, ibuprofen, and female hormones, and personal and family history of medical conditions. Screening arm participants were also asked to complete a food frequency questionnaire at baseline, in which they reported their usual dietary intake over the 12 months prior to enrollment, including use of 137 food items, 12 types of single nutrient or multivitamin supplements, and alcohol. Details on how consumption amounts of nutrients from food and vitamin supplements were calculated are described elsewhere(19). We assessed both pre- and postfortification folate intake in three variables in the present analysis: (a) natural folate (polyglutamates) found naturally in food, (b) synthetic folic acid added to fortified food, and (c) total folate equivalents (a combination of natural folate from food and folic acid in fortified food and vitamin supplements: natural folate + folic acid * 1.7 to reflect higher absorption of the latter). Natural food folate content was assigned using the pre-folic acid fortification (1998) database information from the 1994–1996 Continuing Survey of Food Intake by Individuals(20). Fortified food folate content was assigned based on the post-folic acid grain fortification database information from the Nutrition Data System for Research(21). Considering the mandatory folic acid fortification of grains in the United States that began in 1998, we excluded cases diagnosed prior to 1998 (n = 65) and their matched controls (n = 87) in a sensitivity analysis and the results were very similar. Supplemental folic acid use and dose were derived from recent use (current or 2 years ago) of 4 multivitamins (One-a-

Day type, a therapeutic or high-dose type, Stresstabs, and B-complex), assigning a 200- μ g folic acid dose for B-complex multivitamin and a 400- μ g folic acid dose for the others.

Genomic DNA Methylation Data

DNA was extracted from stored blood samples using Qiagen standard protocols (QIAamp DNA Blood Midi or Maxi kit). Total genomic DNA methylation levels were determined by a High Pressure Liquid Chromatography (HPLC)-Tandem Mass Spectrometry method(22) and expressed as the relative amount of methyl-cytosine to total cytosine residues, or %5-mC. Internal laboratory quality controls consisted of three cell line and commercial samples with known 5-mC contents in every batch. In addition, blinded replicate samples interspersed with study samples (3 samples randomly placed in each of the 40 batches, $n = 120$) showed minimal between-batch variability (coefficient of variation = 4%).

Statistical Analysis

To evaluate the correlation between control subjects' genomic leukocyte DNA methylation levels and their demographic and life-style characteristics, Spearman correlation coefficients and P values were calculated. Odds ratio (OR) and 95 percent confidence intervals (CI) were computed to evaluate the association between categories of %5-mC content, defined using the tertile cutpoints among control subjects, and colorectal cancer risk using unconditional logistic regression, adjusting for age (55–59, 60–64, 65–69, 70–74), gender, race, year of randomization, year since initial sigmoidoscopy screening, smoking, body mass index, use of non-steroid anti-inflammatory drugs, family history of colorectal cancer, and prior history of adenoma, hyperplastic polyps, or inflammatory bowel disease or polyposis syndrome (i.e., ulcerative colitis, Crohn's disease, Gardner's syndrome, and familial polyposis). Inclusion in the models of other potential confounders such as study center, education, and physical activity did not materially change the results. Trend tests were conducted for risks associated with tertiles of %5-mC content and folate intake using logistic regression models based on ordinal variables. Statistical significance of multiplicative interaction between %5-mC content and folate intake (both by tertile cutoffs) was tested using the Wald test for the interaction term in the logistic regression models.

RESULTS

Cases had a lower level of education ($P = 0.02$) and were less likely to consume synthetic folate from diet ($P = 0.02$) compared to controls. Other characteristics were comparable between the study groups (Table 1). Among control subjects, modest correlations were found between genomic leukocyte DNA hypomethylation and having first-degree family history of colorectal cancer ($R = 0.097$, $P = 0.03$) and between genomic methylation levels and natural folate intake ($R = 0.095$, $P = 0.04$). No significant correlations with %5-mC level were observed for other nutrients thought to participate in the one-carbon metabolism pathway, such as synthetic folate from diet, total folate equivalents, vitamin B6, vitamin B12, methionine, and alcohol, nor with other potential risk factors, such as age, gender, race, college graduation, smoking status, regular use of aspirin or ibuprofen, hormone use among females, and body mass index.

Examining the %5-mC level as a continuous variable in the logistic regression model, DNA hypomethylation was not significantly associated with colorectal cancer risk (OR = 1.66 per 1.0 unit increase, 95% CI = 0.77, 3.54). Categorizing the methylation levels by tertiles in control subjects, we observed no dose-response relationship with colorectal cancer risk (P trend = 0.51; Table 2). Additional analyses of finer %5-mC categories, defined using quartiles and deciles as cutpoints, were similarly null (data not shown). Results from analyses stratifying by proximal colon vs. distal colon or rectum cancers or by cancer stage were also null. Our findings did not noticeably change in sensitivity analyses including cases

whose colorectal cancer diagnoses occurred prior to the blood draw ($n = 61$; OR = 1.03, 95% CI = 0.74, 1.45 for the 1st vs. 3rd tertile of 5-mC, $P_{\text{trend}} = 0.89$), excluding cases whose colorectal cancer diagnoses occurred within a year after the blood draw ($n = 193$; OR = 1.30, 95% CI = 0.79, 2.14, $P_{\text{trend}} = 0.34$), excluding subjects with a prior history of adenoma or hyperplastic polyps (via pathological confirmation during the Trial or self-report on the baseline questionnaire; $n = 92$ cases and 83 controls; OR = 1.08, 95% CI = 0.69, 1.67, $P_{\text{trend}} = 0.79$), and excluding cases diagnosed prior to 1998 (before the mandatory folic acid fortification of grains in the U.S., $n = 110$) and matched controls ($n = 134$) (OR = 1.15, 95% CI = 0.78, 1.70, $P_{\text{trend}} = 0.53$).

Intake of natural folate was inversely but not significantly associated with colorectal cancer risk in our data (highest tertile vs. lowest: OR = 0.81, 95% CI = 0.57, 1.15, $P_{\text{for trend}} = 0.23$; Table 3). Upon stratifying by genomic leukocyte DNA methylation levels, we found that the decreasing risk associated with the increasing intake of natural folate was strongest and statistically significant within the stratum of subjects whose DNA methylation levels were in the highest (3rd) tertile (highest tertile of natural folate intake vs. lowest: OR = 0.35, 95% CI = 0.17, 0.71, $P_{\text{for trend}} = 0.003$, $P_{\text{interaction}} = 0.003$). Similarly, reduced DNA methylation level was significantly associated with colorectal cancer risk only among subjects whose natural folate intake levels were at the highest tertile (1st tertile of 5-mC vs. 3rd: OR = 2.65, 95% CI = 1.22, 5.72, $P_{\text{for trend}} = 0.02$, $P_{\text{interaction}} = 0.003$; Supplementary Table 1). No significant association was found for synthetic folic acid added to the diet, synthetic folic acid in supplements, or total folate equivalents from diet and supplements, irrespective of subjects' DNA methylation status ($P_{\text{interaction}} = 0.78, 0.12$, and 0.38 , respectively), nor for other nutrients in the one-carbon pathway such as vitamin B6, vitamin B12, methionine, and alcohol ($P_{\text{interaction}}$ ranging from 0.07 to 0.16; Supplementary Table 2). We note that the test of interaction between natural folate and DNA methylation was significant at a Bonferroni corrected significance level accounted for all seven of the evaluated one-carbon pathway factors ($\alpha = 0.007$). No methylation modifying effect was found for other suspected risk factors of colorectal cancer, such as smoking, obesity, and NSAID use ($P_{\text{interaction}} = 0.70, 0.57$, and 0.31 , respectively).

DISCUSSION

Findings from our study, to our knowledge the first prospective investigation of DNA methylation and colorectal cancer, do not support an association between global genomic hypomethylation in leukocyte DNA and subsequent colorectal cancer risk. We did, however, observe a suggestive risk modification pattern of reduced colorectal cancer risk associated with increased natural folate intake most pronounced among subjects whose genomic leukocyte DNA methylation levels were in the highest tertile. No statistically significant evidence of interaction was found between DNA methylation level and synthetic folate, other nutrients related to methyl availability, or other suspected risk factors of colorectal cancer.

Previously, Pufulete et al.(15) measured genomic DNA from colonic mucosal cells and leukocytes of 28 colorectal cancer patients, 35 adenoma patients, and 76 controls recruited from patients referred for colonoscopy at King's College Hospital At London between August 2000 and May 2001, and found that increased levels of [³H] methyl incorporation into both colonic and leukocyte DNA (i.e., lower levels of DNA methylation) were associated with increased risk for adenoma ($P_{\text{trend}} = 0.02$ and 0.01 , respectively) and a nonsignificantly increased risk for colorectal cancer ($P_{\text{trend}} = 0.09$ and 0.08 , respectively). Similarly, Lim et al.(14), studying genomic DNA from leukocytes of 115 pairs of colorectal adenoma cases and matched controls among asymptomatic women who participated in a multicenter colonoscopy screening study conducted in the U.S. from 2000–2002, found an

increased risk of adenoma associated with lower levels of %5-mC in leukocyte DNA using a reversed-phase high-performance liquid chromatography and mass spectrometry method (P trend = 0.002).

Unlike the previous studies(14;15), we observed no clear dose-dependent risk associations between DNA hypomethylation and colorectal cancer risk. It is unlikely that error from poor assay performance is an explanation for our null finding, as we observed high assay reproducibility (CV = 4%) among quality control samples. Attenuation of a true association could in principle be caused by undetected colorectal neoplasia among cases and controls; however, analyses excluding subjects with a prior history of adenoma (via the screen detection in the Trial or by self-report on baseline questionnaire) or adjusting for this factor in the logistic models resulted in no material change in our findings. A real association could be missed due to insufficient power; we have sufficient power (>90%) to detect the magnitude of associations reported in the previous studies (14;15), although our power is insufficient to detect modest associations (e.g. OR below 1.6 for tertile exposure). Reverse causation is a possible explanation for the previous findings; i.e., the lowered genomic methylation levels observed among diseased patients in the previous studies can potentially be a disease-induced result, although including cases with colorectal cancer prior to the blood collection (n = 61) or excluding cases whose colorectal cancer diagnoses occurred within a year of the blood draw (n = 193) resulted in no notable difference in our findings.

We found a positive correlation between consumption amounts of natural folate intake from food and 5-mC levels in leukocyte DNA, and a protective effect of natural folate intake against colorectal cancer only among subjects with higher 5-mC content. A handful of studies have assessed the interrelationship between DNA methylation and folate intake for colorectal tumors, but results have been conflicting, partly due to the limitations of these studies being small in size(14;23), cross-sectional in nature(14;23), failing to assess natural folate(23) or differentiate natural from synthetic folate(24;25), and measuring only a surrogate indicator of genomic DNA methylation level, e.g., long interspersed nucleotide element-1 (LINE-1)(24;25). Lim et al.(14), assessing adenoma risk in a small cross-sectional study, found a nonsignificant risk reduction with food-derived folate intake but a significant risk modifying effect with DNA methylation for total folate intake (instead of food-derived folate), noting the possibility of chance findings due to the inconsistent findings among different indicators of folate intake. Measuring LINE-1 in somatic tissue of colorectal cancer, Schernhammer et al.(25) found that high folate intake protected against LINE-1 hypomethylated colon cancers, while measuring LINE-1 in normal colonic mucosa, Figueiredo et al.(24) found no association between LINE-1 methylation and risk of adenoma and no differential effect of folate on risk of adenoma according to extent of LINE-1 methylation; both studies did not clearly differentiate natural versus synthetic folate intake. Pufulete et al.(23), examining DNA methylation in leucocytes and colorectal mucosa of patients with adenoma before and after folic acid supplementation (n ~ 15 pairs), found a positive correlation between folate supplementation and genomic DNA methylation levels in both leukocytes and colonic mucosa, although the effects of food-derived folate was not examined in the study. Similarly, other studies have associated localized(26) and dietary(27) folate levels with increased genomic DNA methylation in cancer tissues(26) and leukocytes of cancer patients(27), consistent with animal studies(28).

Since folate and related B vitamins in one carbon pathway are a source of the methyl group added to DNA-creating 5-methylcytosine, the potential that chronic folate status may influence global DNA methylation level is both plausible and the subject of many studies reviewed above. Folate is essential for DNA synthesis, repair, and methylation. Our findings lead us to speculate that adequate folate status may protect against colorectal carcinogenesis

through mechanisms involving adequate DNA methylation in the genome, as methylation level affects DNA stability and gene expression.

Our findings of the methylation-mediating protection effect found only for folate derived from natural source of food (not synthetic folate) are in line with evidence provided by a meta-analysis of five cohort and six case-control studies reporting a colorectal cancer risk reduction only among subjects consuming higher intakes of food-derived folate (not total folate from foods and supplements)(29), and two randomized trials finding no significant effect of folic acid supplementation against colorectal cancer after 3 years treatment(30;31). It was suggested that the smaller intake of food folate appeared to offer protection against colorectal cancer risk, whereas the use of (unphysiologically) large doses of folic acid in the intervention studies could result in unmetabolized folic acid in peripheral blood and cause potential adverse effects, e.g. reduced cytotoxicity of Natural Killer cells(32). Despite the plausible mechanisms, we cannot dismiss the possibility that our findings are due to chance, given that we have examined the interrelationship of the methylation marker with a range of suspected risk factors.

Although our sample size ($n = 370$ colorectal cancer cases) is considerably larger than those of previous studies investigating genomic leukocyte DNA methylation levels and colorectal tumor risk ($n = 28$ colorectal cancer cases and 35 adenoma cases by Pufulete et al(15) and $n = 115$ adenoma cases by Lim et al(14), respectively) and we have sufficient power ($>90\%$) to detect the magnitude of associations reported in the previous studies, we still do not have adequate power to detect modest associations (e.g., OR below 1.6 for tertile exposure). We have even less power to assess interactions and could have observed merely chance findings or have failed to detect weaker risk modification effects between DNA methylation status and one-carbon nutrients or other lifestyle factors. It would be important to evaluate tissue-specific changes in methylation. Although Pufulete et al. found similar positive correlations between folate supplementation and genomic DNA methylation levels in both leukocytes and colonic mucosa(23) and similar risk patterns of colorectal cancer with hypomethylation in both leukocyte and colonic DNA(15), data is currently lacking with respect to how methylation changes correlate between leukocyte and colorectal tumor tissue. We will have opportunities to address this question with the colorectal cancer tissue specimens recently collected in the PLCO Trial.

A major strength of our study includes its prospective design, examining DNA samples (i.e. 5-mC levels) collected prior to any cancer diagnosis and folate data collected prior to DNA samples and cancer diagnosis among cases and controls, to rule out reverse causation bias suspected in the previous cross-sectional studies(14;15;27;33). In addition, cases and controls in this study came from 10 different screening centers representing a broad population distribution in the U.S, and they were identified from the same source population, which was screened by a standardized procedure for colorectal cancer and adenoma (i.e., cases were not screened based on symptoms and had an equal chance for disease detection as controls). The screen tests done in the Trial also allowed us to identify the occurrence of adenoma that otherwise could have been missed in regular studies of colorectal cancer. Further, we observed very small assay variability ($CV = 0.04$) for 5-mC content.

In this prospective investigation of DNA methylation and colorectal cancer, we found no clear dose-dependent risk patterns associated with the genomic leukocyte DNA methylation status. We did, however, observe that the genomic leukocyte DNA methylation levels were positively correlated with natural folate intake from food, and significantly modified colorectal cancer risk associated with natural folate intake, suggesting a mediating role of DNA methylation for folate-related protective effects against colorectal cancer. Replication

of this apparent interaction in future prospective studies with differentiation between natural versus synthetic folate intake in risk assessment is warranted. The findings may draw implications for future efforts in defining mechanisms of carcinogenesis and identifying biomarkers for colorectal cancer risk stratification.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This research was supported by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics and contracts from the Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services. The authors thank Drs. Christine Berg and Philip Prorok, Division of Cancer Prevention, National Cancer Institute, the Screening Center investigators and staff of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, Mr. Tom Riley and staff, Information Management Services, Inc., and Ms. Barbara O'Brien and staff, Westat, Inc.. We thank Yonggang Zhang, Michele Rudek-Renaut, Ming Zhao, and David Esopi for their contributions in measuring 5-methylcytosine content in the study samples. Most importantly, we acknowledge the study participants for their contributions to making this study possible.

Abbreviation

5-mC	methyalted cytosine
PLCO	the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
OR	odds ratio
CI	95% confidence intervals
LINE-1	long interspersed nucleotide element-1

References

1. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. *Nat Rev Genet.* 2006; 7(1):21–33. [PubMed: 16369569]
2. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. *Nat Rev Genet.* 2002; 3(6):415–428. [PubMed: 12042769]
3. Ehrlich M. DNA methylation in cancer: too much, but also too little. *Oncogene.* 2002; 21(35):5400–5413. [PubMed: 12154403]
4. Karpf AR, Matsui S. Genetic disruption of cytosine DNA methyltransferase enzymes induces chromosomal instability in human cancer cells. *Cancer Res.* 2005; 65(19):8635–8639. [PubMed: 16204030]
5. Feinberg AP, Gehrke CW, Kuo KC, Ehrlich M. Reduced genomic 5-methylcytosine content in human colonic neoplasia. *Cancer Res.* 1988; 48(5):1159–1161. [PubMed: 3342396]
6. Giovannucci E, Oginio S. DNA methylation, field effects, and colorectal cancer. *J Natl Cancer Inst.* 2005; 97(18):1317–1319. [PubMed: 16174847]
7. Suter CM, Martin DI, Ward RL. Hypomethylation of L1 retrotransposons in colorectal cancer and adjacent normal tissue. *Int J Colorectal Dis.* 2004; 19(2):95–101. [PubMed: 14534800]
8. Suzuki K, Suzuki I, Leodolter A, Alonso S, Horiuchi S, Yamashita K, et al. Global DNA demethylation in gastrointestinal cancer is age dependent and precedes genomic damage. *Cancer Cell.* 2006; 9(3):199–207. [PubMed: 16530704]
9. Estecio MR, Gharibyan V, Shen L, Ibrahim AE, Doshi K, He R, et al. LINE-1 Hypomethylation in Cancer Is Highly Variable and Inversely Correlated with Microsatellite Instability. *PLoS ONE.* 2007; 2:e399. [PubMed: 17476321]

10. Ogino S, Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Kirkner GJ, et al. LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. *Int J Cancer*. 2008; 122(12):2767–2773. [PubMed: 18366060]
11. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Chan AT, Schernhammer ES, et al. A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. *J Natl Cancer Inst*. 2008; 100(23):1734–1738. [PubMed: 19033568]
12. Mathers JC. Folate intake and bowel cancer risk. *Genes Nutr*. 2009; 4(3):173–178. [PubMed: 19499262]
13. van EM, Herman JG. Viewing the epigenetics of colorectal cancer through the window of folic acid effects. *Cancer Prev Res (Phila)*. 2010; 3(12):1509–1512. [PubMed: 21149326]
14. Lim U, Flood A, Choi SW, Albanes D, Cross AJ, Schatzkin A, et al. Genomic methylation of leukocyte DNA in relation to colorectal adenoma among asymptomatic women. *Gastroenterology*. 2008; 134(1):47–55. [PubMed: 18166347]
15. Pufulete M, Al-Ghnam R, Leather AJ, Appleby P, Gout S, Terry C, et al. Folate status, genomic DNA hypomethylation, and risk of colorectal adenoma and cancer: a case control study. *Gastroenterology*. 2003; 124(5):1240–1248. [PubMed: 12730865]
16. Schoen RE, Weissfeld JL, Pinsky PF, Riley T. Yield of advanced adenoma and cancer based on polyp size detected at screening flexible sigmoidoscopy. *Gastroenterology*. 2006; 131(6):1683–1689. [PubMed: 17188959]
17. Schoen RE, Weissfeld JL, Pinsky PF, Riley T. Yield of advanced adenoma and cancer based on polyp size detected at screening flexible sigmoidoscopy. *Gastroenterology*. 2006; 131(6):1683–1689. [PubMed: 17188959]
18. Hayes RB, Sigurdson A, Moore L, Peters U, Huang WY, Pinsky P, et al. Methods for etiologic and early marker investigations in the PLCO trial. *Mutat Res*. 2005; 592(1–2):147–154. [PubMed: 16054167]
19. Oaks BM, Dodd KW, Meinhold CL, Jiao L, Church TR, Stolzenberg-Solomon RZ. Folate intake, post-folic acid grain fortification, and pancreatic cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. *Am J Clin Nutr*. 2010; 91(2):449–455. [PubMed: 20007302]
20. Subar AF, Thompson FE, Smith AF, Jobe JB, Ziegler RG, Potischman N, et al. Improving food frequency questionnaires: a qualitative approach using cognitive interviewing. *J Am Diet Assoc*. 1995; 95(7):781–788. [PubMed: 7797809]
21. NDSR descriptive overview. University of Minnesota Nutrition Coordinating Center; 2011.
22. Yegnasubramanian S, Haffner MC, Zhang Y, Gurel B, Cornish TC, Wu Z, et al. DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. *Cancer Res*. 2008; 68(21):8954–8967. [PubMed: 18974140]
23. Pufulete M, Al-Ghnam R, Khushal A, Appleby P, Harris N, Gout S, et al. Effect of folic acid supplementation on genomic DNA methylation in patients with colorectal adenoma. *Gut*. 2005; 54(5):648–653. [PubMed: 15831910]
24. Figueiredo JC, Grau MV, Wallace K, Levine AJ, Shen L, Hamdan R, et al. Global DNA hypomethylation (LINE-1) in the normal colon and lifestyle characteristics and dietary and genetic factors. *Cancer Epidemiol Biomarkers Prev*. 2009; 18(4):1041–1049. [PubMed: 19336559]
25. Schernhammer ES, Giovannucci E, Kawasaki T, Rosner B, Fuchs CS, Ogino S. Dietary folate, alcohol and B vitamins in relation to LINE-1 hypomethylation in colon cancer. *Gut*. 2010; 59(6):794–799. [PubMed: 19828464]
26. Piyathilake CJ, Johanning GL, Macaluso M, Whiteside M, Oelschlager DK, Heimburger DC, et al. Localized folate and vitamin B-12 deficiency in squamous cell lung cancer is associated with global DNA hypomethylation. *Nutr Cancer*. 2000; 37(1):99–107. [PubMed: 10965526]
27. Hsiung DT, Marsit CJ, Houseman EA, Eddy K, Furniss CS, McClean MD, et al. Global DNA methylation level in whole blood as a biomarker in head and neck squamous cell carcinoma. *Cancer Epidemiol Biomarkers Prev*. 2007; 16(1):108–114. [PubMed: 17220338]
28. Balaghi M, Wagner C. DNA methylation in folate deficiency: use of CpG methylase. *Biochem Biophys Res Commun*. 1993; 193(3):1184–1190. [PubMed: 8323540]

29. Sanjoaquin MA, Allen N, Couto E, Roddam AW, Key TJ. Folate intake and colorectal cancer risk: a meta-analytical approach. *Int J Cancer*. 2005; 113(5):825–828. [PubMed: 15499620]
30. Cole BF, Baron JA, Sandler RS, Haile RW, Ahnen DJ, Bresalier RS, et al. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. *JAMA*. 2007; 297(21):2351–2359. [PubMed: 17551129]
31. Logan RF, Grainge MJ, Shepherd VC, Armitage NC, Muir KR. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. *Gastroenterology*. 2008; 134(1):29–38. [PubMed: 18022173]
32. Troen AM, Mitchell B, Sorensen B, Wener MH, Johnston A, Wood B, et al. Unmetabolized folic acid in plasma is associated with reduced natural killer cell cytotoxicity among postmenopausal women. *J Nutr*. 2006; 136(1):189–194. [PubMed: 16365081]
33. Moore LE, Pfeiffer RM, Poscablo C, Real FX, Kogevinas M, Silverman D, et al. Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case-control study. *Lancet Oncol*. 2008; 9(4):359–366. [PubMed: 18339581]

Table 1

Self-reported baseline and clinical characteristics of study subjects, the PLCO Cancer Screening Trial, 1993 – 2001

	Case N = 370	Control N = 493	
	N (%) or Mean (S.D.)	N (%) or Mean (S.D.)	P
Age group			
59	83 (22.4%)	98 (19.9%)	0.78
60–64	127 (34.3%)	170 (34.5%)	
65–69	93 (25.1%)	126 (25.6%)	
70–74	67 (18.1%)	99 (20.1%)	
Male	196 (53.0%)	290 (58.8%)	0.09
White	327 (88.4%)	432 (87.6%)	0.74
College graduated or higher	113 (30.6%)	188 (38.4%)	0.02
1 st degree family history of colorectal cancer	50 (13.5%)	59 (12.0%)	0.50
Current cigarette smoker	41 (11.1%)	52 (10.6%)	0.86
Former cigarette smoker	162 (43.8%)	225 (45.6%)	
Regular aspirin or ibuprofen use (4 / month)	218 (58.9%)	304 (61.7%)	0.41
Current hormone use among females	88 (44.0%)	112 (50.9%)	0.21
Former hormone use among females	33 (16.5%)	39 (17.7%)	
Body mass index, kg/m ²	27.5 (4.6)	27.5 (5.0)	0.87
Alcohol, g/day	13.8 (29.4)	11.5 (20.4)	0.23
Natural food folate, µg/day	302.0 (121.2)	314.5 (125.8)	0.17
Fortified food folate, µg/day	163.7 (91.8)	181.9 (122.3)	0.02
Total folate equivalents (food and supplements), µg/day	1056.8 (722.8)	1088.8 (727.8)	0.54
Vitamin B6 (food and supplements), mg/day	2.37 (0.9)	2.47 (1.1)	0.16
Vitamin B12 (food and supplements), mg/day	5.7 (3.0)	5.9 (3.4)	0.40
Methionine (food), g/day	1.7 (0.7)	1.7 (0.7)	0.46
Distal carcinoma	238 (51.5%)		
Stage I	82 (16.1%)		
Stage II	184 (39.8%)		
Stage III	111 (24.0%)		
Stage IV	93 (20.1%)		

Table 2

Risk^I of colorectal cancer associated with percent genomic leukocyte DNA methylation levels (or %5-mC), the PLCO Cancer Screening Trial, 1993 – 2001

%5-mC	Case N = 370	Control N = 493		
	N	N	%5-mC cutoff	OR (95% CI)
Tertile				
3rd	104	160	4.11	1.00
2nd	146	167	3.95 – < 4.11	1.44 (1.02, 2.03)
1st	120	166	<3.95	1.14 (0.80, 1.63)
<i>P</i> for trend				0.51

^IOdds ratio (OR) and 95% confidence interval (CI) calculated by unconditional logistic regression adjusted for age, gender, race, time since initial sigmoidoscopy screening, year of randomization, smoking, body mass index, use of non-steroid anti-inflammatory drugs, a family history of colorectal cancer, and a prior history of adenoma, hyperplastic polyps, or inflammatory bowel disease or polyposis syndrome (i.e., ulcerative colitis, Crohn's disease, Gardner's syndrome, and familial polyposis)

Table 3

Risk¹ of colorectal cancer associated with folate intake stratified by percent genomic leukocyte DNA methylation levels (or %5-mC), the PLCO Cancer Screening Trial, 1993 – 2001

	%5-mC											
	All			1st tertile			2nd tertile			3rd tertile		
	N	OR	(95% CI)	N	OR	(95% CI)	N	OR	(95% CI)	N	OR	(95% CI)
Natural food folate												
1 st tertile	165/201	1.00		50/86	1.00		59/60	1.00		56/55	1.00	
2 nd tertile	126/163	0.87	(0.62, 1.23)	51/57	1.05	(0.58, 1.91)	44/52	1.02	(0.56, 1.85)	31/54	0.62	(0.33, 1.15)
3 rd tertile	104/155	0.81	(0.57, 1.15)	44/49	1.33	(0.72, 2.47)	43/55	0.87	(0.48, 1.58)	17/51	0.35	(0.17, 0.71)
P trend		0.23			0.38			0.64			0.003	
Fortified food folate												
1 st tertile	143/202	1.00		51/78	1.00		48/65	1.00		44/59	1.00	
2 nd tertile	154/161	1.33	(0.95, 1.85)	56/59	1.82	(1.03, 3.23)	66/52	0.94	(0.50, 1.76)	32/50	1.01	(0.55, 1.84)
3 rd tertile	98/156	0.98	(0.68, 1.41)	38/55	1.02	(0.53, 1.98)	32/50	0.99	(0.51, 1.90)	28/51	1.02	(0.57, 1.85)
P trend		0.93			0.90			0.77			0.94	
Total folate equivalents (food + supplements)												
1 st tertile	164/200	1.00		59/78	1.00		59/68	1.00		46/54	1.00	
2 nd tertile	118/162	0.96	(0.69, 1.35)	43/58	1.01	(0.55, 1.84)	44/52	0.87	(0.49, 1.56)	31/52	0.97	(0.51, 1.85)
3 rd tertile	113/157	0.92	(0.65, 1.29)	43/56	1.02	(0.57, 1.85)	43/47	1.18	(0.65, 2.16)	27/54	0.67	(0.35, 1.28)
P trend		0.62			0.94			0.65			0.24	

¹ Odds ratio (OR) and 95% confidence interval (CI) calculated by unconditional logistic regression adjusted for age, gender, race, time since initial sigmoidoscopy screening, year of randomization, smoking, body mass index, use of non-steroid anti-inflammatory drugs, a family history of colorectal cancer, and a prior history of adenoma, hyperplastic polyps, or inflammatory bowel disease or polyposis syndrome (i.e., ulcerative colitis, Crohn's disease, Gardner's syndrome, and familial polyposis)